Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Consolidation Durvalumab After Chemoradiotherapy in a Real-World Cohort With NSCLC

By: Julia Fiederlein
Posted: Tuesday, November 9, 2021

Consolidation therapy with durvalumab after chemoradiotherapy seemed to be effective in a real-world cohort of patients with unresectable stage III non–small cell lung cancer (NSCLC), according to Nicolas Girard, MD, of the Institut Curie & Montsouris, Paris, and colleagues. The treatment duration and interim progression-free survival analysis of the large international, observational PACIFIC-R trial were presented during the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract 1171MO). In this real-world cohort, the median progression-free survival with the monoclonal antibody was higher than the median progression-free survival with this agent in the phase III PACIFIC trial (21.7 months vs. 16.9 months), although the investigators noted that future data on overall survival should determine the true effectiveness of this regimen.

The PACIFIC-R trial included nearly 1,400 patients from 11 countries, with 1,155 patients represented the full analysis set. They had completed platinum-based chemotherapy concurrently or sequentially to radiotherapy within the previous 12 weeks without evidence of disease progression were administered at least one dose of durvalumab. After radiation therapy, the median duration of time to durvalumab initiation was 52 days. The overall median duration of durvalumab treatment was 337 days; a total of 20.1% and 4.3% of patients underwent this therapy for more than 12 and 14 months, respectively. Patients were administered a median of 22 infusions.

Patients discontinued treatment due to completion (47.6%; median time to treatment discontinuation: 11.8 months), disease progression (25.8%; 5.1 months), and adverse events (17.5%; 2.8 months). The most common adverse event leading to treatment discontinuation was pneumonitis (temporary: 5.1%; permanent: 8.7%). A total of 18.5% of patients experienced any-grade pneumonitis and/or interstitial lung disease (median time from durvalumab start: 74 days). Of these adverse events, 8.8% were moderate; life-threatening and fatal events were reported in 0.2% and 0.1% of patients, respectively.

Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.